Managing Urogenital and Vulvovaginal Atrophy in Breast Cancer Survivors Receiving Endocrine Therapy

Posted on August 18, 2019

Read Story

Source: Cleveland Clinic

Case vignette

A 46-year-old patient presented to our specialty women’s health clinic with vaginal bleeding. Previously, this patient was treated at our facility for early-stage breast cancer. As part of her treatment, she had a hysterectomy, oophorectomy and was on a long-term adjuvant course of aromatase inhibitors (AIs).

The patient was very concerned that the etiology of the bleeding was cancerous.

On exam, we determined that a urethral caruncle—a large friable red mass—was the source of the bleeding, which was the result of marked hormonal deficiency of the lower genitourinary system.

Treatment included a temporary suspension of the aromatase therapy and a course of topical vaginal estrogen to resolve the urethral caruncle. Following symptom resolution, adjunctive therapy resumed.

Loss of estrogen can lead to urogenital and vulvovaginal atrophy

This is a dramatic example of a complication of AI therapy in women with estrogen receptor-positive breast cancer. AIs inhibit the enzyme aromatase, which promotes the conversion of androgen into estrogen, reducing breast cancer recurrence and improving overall survival.

However, systemic loss of estrogen results in changes to the genital structures and vaginal mucosa, including the following:

  • A reduction in cervical gland secretions.
  • Tissue deterioration.
  • Decreased blood flow.
  • Thinning tissue, loss of elasticity.
  • Vaginal dryness, itching and irritation.
  • Loss of libido.

These symptoms are known as genitourinary syndrome of menopause (GSM), and can have a significant impact on a patient’s quality of life.

“It’s not just a minor lifestyle problem,” says Holly L. Thacker, MD, Professor and Director of Cleveland Clinic Center for Specialized Women’s Health. “There’s a lot of significant known risk of untreated atrophy: bleeding, pain, sexual dysfunction, destroyed relationships, recurrent bladder infections that can even lead to urosepsis.”

GSM is the topic of a clinical review recently published by a team of Cleveland Clinic oncologists and a women’s health specialist in the Journal of Oncology Practice.

“This topic is not always addressed with breast cancer survivors on endocrine therapy, and is an important topic for quality of life and safety in patients,” states Tamara Sussman, MD, lead author on the study. “Hopefully, our review will help guide this important conversation and management of GSM of menopause in this patient population. Most importantly, we hope that this article will help oncologists to have meaningful and helpful conversations about GSM with their patients on endocrine therapy.”

Nonhormonal treatment

Nonhormonal treatments such as vaginal gels, moisturizers and lubricants, can temporarily relieve symptoms of atrophy by increasing moisture. They are considered safest for women with hormone-related breast cancer, but do not change the underlying disorder. Nevertheless, when used regularly, vaginal moisturizers can alleviate symptoms of vaginal dryness and itching. Vaginal lubricants can be added to reduce friction during intercourse.

Local therapy

Vaginal estrogen therapies—in the form of estradiol-releasing intravaginal tablets, low-dose estrogen vaginal inserts, estrogen-based vaginal creams and estradiol-releasing vaginal rings—improve GSM symptoms with varying levels of systemic absorption. The newest vaginal estradiol currently on the market is Imvexxy®, a vaginal insert that comes in 4-µg and 10-µg doses in bio-adhesive coconut oil.

Non-estrogen therapy with precursor vaginal DHEA—as in Intrarosa®—can be offered in women declining even local, very low dose estrogen therapy and/or in women for whom the local estrogen therapy is not enough. Vaginal DHEA is aromatized to estrogen and testosterone in intracellular vaginal tissue.